Drugs / Oliceridine
Oliceridine
also known as
TRV130 · Oliceridina · Oliceridine Fumarate · Oliceridine fumarate injection · Olinvyk · Olynvik
Other / unclassified targets OPRM1 via activation
Regulatory milestones approvals, filings & regulatory actions · 6 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Filed | China (NMPA) | OLINVYK | acute pain | 2022-01-27 | “today announced that China’s National Medical Products Administration (NMPA) has accepted submission of a New Drug Application (NDA) for oliceridine injection.” trevena.com ↗ “Jiangsu Nhwa submitted a New Drug Application for OLINVYK to China’s National Medical Products Administration (NMPA) in January 2022.” trevena.com ↗ |
| Approved | US (FDA) | OLINVYK | — | 2020-08-07 | fda.gov ↗ |
| Filed | US (FDA) | — | acute pain | 2020-02-10 | “we reached a significant milestone for the oliceridine program, with our resubmission and FDA’s acceptance of the NDA.” trevena.com ↗ “today announced that it has resubmitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA)” trevena.com ↗ “FDA has acknowledged receipt of the resubmitted New Drug Application (NDA) for IV oliceridine” trevena.com ↗ |
| Rejected (CRL) | US (FDA) | — | acute pain | 2018-11-02 | “today announced the Company has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for oliceridine.” trevena.com ↗ “FDA related to the oliceridine complete response letter (CRL).” trevena.com ↗ |
| Filed | US (FDA) | — | acute pain | 2018-01-02 | “The Company‘s New Drug Application (NDA) submission for oliceridine was accepted for review by the FDA on January 2, 2018.” trevena.com ↗ “Trevena’s New Drug Application (NDA) submission for oliceridine was accepted for review by the FDA on January 2, 2018” trevena.com ↗ |
| Filed | US (FDA) | OLINVO | acute pain | 2017-11-02 | “recently submitted its New Drug Application (NDA) for OLINVO TM (oliceridine injection) to the U.S. Food and Drug Administration (FDA).” trevena.com ↗ “OLINVO™ (oliceridine) Injection New Drug Application submitted and accepted for review by FDA” trevena.com ↗ |
Trials 33
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT02344303 | Dec 2014 → May 2015 | — | Trevena Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02169934 | Jun 2014 → Jan 2015 | — | Trevena Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02083315 | Jul → Aug 2013 | — | Trevena Inc. | Completed | No outcome recorded |
| Phase 23 trials · 1 met primary | ||||||
| Phase 2 | NCT02520297 | Oct 2015 | — | Trevena Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT02335294 | Dec 2014 → Jul 2015 | — | Trevena Inc. | Completed | Met primary |
| Phase 2 | NCT02100748 | Apr → Oct 2014 | — | Trevena Inc. | Completed | No outcome recorded |
| Phase 33 trials · 2 met primary | ||||||
| Phase 3 | NCT02815709 | May → Dec 2016 | — | Trevena Inc. | Completed | Met primary |
| Phase 3 | NCT02820324 | May → Dec 2016 | — | Trevena Inc. | Completed | Met primary |
| Phase 3 | NCT02656875 | Dec 2015 → May 2017 | — | Trevena Inc. | Completed | No outcome recorded |
| Phase 411 trials | ||||||
| Phase 4 | NCT07660380 | Jun → Jul 2026 overdue | — | Shiyou Wei | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07018375 | Jan 2026 → Mar 2027 expected | chronic pain syndrome | Tianjin Medical University General Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT06530563 | Aug 2025 → Apr 2026 overdue | — | Xiangya Hospital of Central South University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07026162 | Jul 2025 → Feb 2026 | — | YanYing Xiao | Completed | No outcome recorded |
| Phase 4 | NCT06619145 | Nov 2024 → Oct 2026 expected | — | Nanjing First Hospital, Nanjing Medical University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06320041 | Aug 2024 → Dec 2026 expected | — | The Fourth Affiliated Hospital of Zhejiang University School of Medicine | Recruiting | No outcome recorded |
| Phase 4 | NCT06458400 | Jul → Sep 2024 | — | Yuwei Qiu | Completed | No outcome recorded |
| Phase 4 | NCT06411665 | Jul 2024 → Mar 2025 | — | Peking University First Hospital | Completed | No outcome recorded |
| Phase 4 | NCT06454292 | Jun 2024 → Dec 2025 | — | Chun Pan | Unknown | No outcome recorded |
| Phase 4 | NCT05465226 | Apr → Sep 2023 | respiratory underresponsiveness to hypoxia and hypercapnia | University of Tennessee | Completed | No outcome recorded |
| Phase 4 | NCT04979247 | Sep 2021 → Dec 2023 | — | The Cleveland Clinic | Completed | No outcome recorded |
| Phase not applicable13 trials | ||||||
| — | NCT07707258 | Jul → Sep 2026 overdue | — | Baoshan Branch, Renji Hospital, Shanghai Jiao Tong University School of Medicine | Not yet recruiting | No outcome recorded |
| — | NCT07650812 | Jul 2026 → Dec 2027 expected | bowel dysfunction | Beijing Tiantan Hospital | Not yet recruiting | No outcome recorded |
| — | NCT07479446 | Mar 2026 → Aug 2027 expected | cerebellopontine angle tumor | Xuanwu Hospital, Beijing | Recruiting | No outcome recorded |
| — | NCT07307495 | Jan 2026 → Jul 2027 expected | — | Xijing Hospital | Not yet recruiting | No outcome recorded |
| — | NCT07372209 | Oct → Dec 2025 | — | Tangshan Maternal and Child Health Hospital | Completed | No outcome recorded |
| — | NCT07187765 | Sep → Nov 2025 | — | Shiyou Wei | Completed | No outcome recorded |
| — | NCT07154979 | Sep 2025 | — | Shiyou Wei | Completed | No outcome recorded |
| — | NCT07713134 | Aug 2025 → May 2026 | — | Tangshan Maternal and Child Health Hospital | Completed | No outcome recorded |
| — | NCT07112157 | Aug 2025 → Aug 2026 overdue | strabismus | Henan Provincial People's Hospital | Not yet recruiting | No outcome recorded |
| — | NCT07097038 | Jul → Dec 2025 overdue | — | Henan Provincial People's Hospital | Not yet recruiting | No outcome recorded |
| — | NCT06990893 | Jun 2025 → Oct 2026 expected | — | Anqing Municipal Hospital | Recruiting | No outcome recorded |
| — | NCT06668298 | Nov 2024 → Jun 2025 overdue | — | Henan Provincial People's Hospital | Not yet recruiting | No outcome recorded |
| — | NCT06409689 | Jun 2024 → Jun 2025 overdue | — | Tongji Hospital | Recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT07306702 Background | Jun 2026 → May 2027 | — | Shenyang Sixth People's Hospital | Withdrawn | No outcome recorded |
News releases announcing trial results or a regulatory action · 53
| Date | Issuer | Release |
|---|---|---|
| 2023-06-26 | Trevena Inc. | Results Trevena Announces New Topline OLINVYK Data Highlighting Reduced Cost per Admission from ARTEMIS Real-World Outcomes Study trevena.com ↗
OLINVYK-treated patients (n=201) had a statistically significant ~$8,750 (19%) lower cost per admission and ~1.4 day (20%) reduced average length of hospital stay, compared to matched patients treated with other IV opioids (n=982) |
| 2023-05-08 | Trevena Inc. | Regulatory Trevena Announces Approval of OLINVYK in China trevena.com ↗
today announced that its partner in China, Jiangsu Nhwa, received formal approval from the National Medical Products Administration for OLINVYK. |
| 2023-03-30 | Trevena Inc. | Results Trevena Announces Initial Topline OLINVYK Data from ~200 Patient Real-World Clinical Outcomes Study trevena.com ↗
Over 90% of OLINVYK-treated patients in VOLITION reported feeling “alert and calm” from the morning of the first post-operative day and at every observation point thereafter, based on the Richmond Agitation-Sedation Scale |
| 2023-03-30 | Trevena Inc. | Results Trevena Reports Fourth Quarter 2022 Results and Provides Business Update trevena.com ↗
Initial topline data from new real-world VOLITION study demonstrated over 50% GI complete response and less than 4% incidence of symptoms suggestive of delirium in patients treated with OLINVYK. |
| 2023-02-14 | Trevena Inc. | Results Trevena Announces Publication of OLINVYK Respiratory Physiology Study In ANESTHESIOLOGY trevena.com ↗
The results of the study demonstrated that oliceridine and morphine differed in their pharmacodynamics with a more rapid onset and offset of respiratory depression for oliceridine and a smaller magnitude of respiratory depression over time. |
| 2022-10-24 | Trevena Inc. | Results Trevena Announces OLINVYK Poster Presentation at the ANESTHESIOLOGY® 2022 Annual Meeting trevena.com ↗
These data add to our prior published work with oliceridine, and continue to suggest that it may provide a reduced impact on ventilatory function as compared to IV morphine. |
| 2022-08-11 | Trevena Inc. | Results Trevena Reports Second Quarter 2022 Results and Provides Business Update trevena.com ↗
OLINVYK post-approval strategy advances with positive topline cognitive function data and continued enrollment in VOLITION clinical outcomes study |
| 2022-07-28 | Trevena Inc. | Results Trevena Announces Positive Topline OLINVYK Cognitive Function Data and Provides General Business Update trevena.com ↗
Trevena, Inc. (Nasdaq:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today reported positive topline results from its post-approval study designed to assess the impact on cognitive function in subjects treated with OLINVYK compared to IV morphine. |
| 2022-04-20 | Trevena Inc. | Results Trevena Announces Results from Respiratory Physiology Study of Head-to-Head Comparison of OLINVYK® and IV Morphine in Elderly/Overweight Subjects trevena.com ↗
These data suggest that OLINVYK, a new chemical entity, may offer a more favorable respiratory safety profile when compared to IV morphine. |
| 2022-03-31 | Trevena Inc. | Results Trevena Reports Fourth Quarter and Full Year 2021 Results trevena.com ↗
Topline data of OLINVYK vs IV morphine in high-risk subjects demonstrates statistically significant benefit in lowering respiratory depression |
| 2022-01-27 | Trevena Inc. | Regulatory Trevena Announces Submission of New Drug Application in China for OLINVYK® by its Partner Jiangsu Nhwa Pharmaceutical trevena.com ↗
today announced that China’s National Medical Products Administration (NMPA) has accepted submission of a New Drug Application (NDA) for oliceridine injection. |
| 2021-10-13 | Trevena Inc. | Results Trevena Announces Two OLINVYK® Presentations at ANESTHESIOLOGY® 2021 trevena.com ↗
Obese patients (BMI > 30 kg/m 2 ) were not at an increased risk for developing ORAEs, despite having a higher incidence of medical comorbidities compared to |
| 2021-08-10 | Trevena Inc. | Results Trevena Announces Publication Highlighting Risk / Benefit Analysis of OLINVYK® in Pain and Therapy trevena.com ↗
The findings suggest that under equianalgesic conditions, patients receiving OLINVYK were less likely to experience adverse events (AEs) compared to patients treated with morphine. |
| 2021-05-12 | Trevena Inc. | Results Trevena Announces Presentation of OLINVYK® Respiratory Safety Data in High-Risk Patients at the 46th Annual ASRA Meeting trevena.com ↗
The incidence of opioid-induced respiratory depression (OIRD) was similar between “high-risk” patients, defined as elderly and obese, and “low-risk” patients, defined as younger and non-obese. |
| 2021-01-28 | Trevena Inc. | Results Trevena, Inc. Announces Publication Highlighting OLINVYK™ Respiratory Safety Data in High-Risk Patients in Pain & Therapy trevena.com ↗
The results of this analysis highlight no statistically significant difference in the incidence of opioid-induced respiratory depression (OIRD) between elderly and younger patients, or between obese and non-obese patients, all of whom received OLINVYK. |
| 2020-11-20 | Trevena Inc. | Results Trevena, Inc. Announces Publication Highlighting GI Tolerability Profile of OLINVYK™ (oliceridine) injection in Pain and Therapy trevena.com ↗
The results of this analysis highlight an improved gastrointestinal (GI) tolerability profile, with OLINVYK demonstrating a ~2-3x likelihood of achieving a “complete GI response” compared to IV morphine under equianalgesic conditions. |
| 2020-10-30 | Trevena Inc. | Regulatory Trevena, Inc. Announces DEA Scheduling of OLINVYK™ (oliceridine) injection trevena.com ↗ |
| 2020-10-05 | Trevena Inc. | Results Trevena, Inc. Announces Three OLINVYK™ Presentations at the Virtual American Society of Anesthesiologists 2020 Annual Meeting trevena.com ↗ |
| 2020-09-21 | Trevena Inc. | Results Trevena, Inc. Announces Presentations at the Virtual 2020 American College of Clinical Pharmacology Annual Meeting trevena.com ↗
OLINVYK was associated with a higher probability of analgesia than respiratory depression, while the reverse was true for morphine. |
| 2020-08-26 | Trevena Inc. | Results Trevena Announces Publications of OLINVYK™ Respiratory Safety Analyses vs. IV Morphine trevena.com ↗
Both publications highlight data showing an improved respiratory safety profile for OLINVYK compared to IV morphine. |
| 2020-08-10 | Trevena Inc. | Regulatory Trevena Announces FDA Approval of OLINVYK™ (oliceridine) injection trevena.com ↗
Trevena, Inc. (Nasdaq: TRVN) , a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has approved OLINVYK in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. |
| 2020-06-03 | Trevena Inc. | Regulatory Trevena Announces Advancement of Oliceridine Clinical Development in China by Jiangsu Nhwa Pharmaceutical Co. trevena.com ↗
the Company’s partner in China has been approved by the Chinese National Medical Products Administration (NMPA) to initiate clinical trials for IV oliceridine |
| 2020-03-05 | Trevena Inc. | Regulatory Trevena Announces FDA Has Set PDUFA Date of August 7, 2020 for Oliceridine trevena.com ↗
In their acknowledgement letter, FDA stated that the Company’s resubmission is a complete, Class 2 response to the Agency’s action letter dated November 2, 2018. |
| 2020-02-10 | Trevena Inc. | Regulatory Trevena Resubmits New Drug Application for Oliceridine trevena.com ↗
The NDA for oliceridine was resubmitted based on the outcome and final minutes of a Type A meeting with FDA, which was conducted to obtain clarity on their Complete Response Letter (CRL). |
| 2019-11-20 | Trevena Inc. | Results Trevena Announces Publication of Results from Special Population Studies for Oliceridine trevena.com ↗
The results demonstrate that no dose adjustments are needed in patients with renal impairment or in patients with mild / moderate hepatic impairment. |
| 2019-11-20 | Trevena Inc. | Results Trevena Announces Publication of Results from Phase 3 “Real World” Safety Study for Oliceridine in The Journal of Pain Research trevena.com ↗
The results of this study show that oliceridine was generally safe and well-tolerated in a variety of surgical and medical conditions with acute pain. |
| 2019-11-04 | Trevena Inc. | Results Trevena Reports Third Quarter 2019 Results and Topline Data From Multi-Dose Healthy Volunteer QT Study trevena.com ↗
A small, transient effect, consistent with that observed in the single-dose QT study, began dissipating after 12 hours and was absent at the end of the 24-hour study period despite repeated dosing of oliceridine. |
| 2019-10-21 | Trevena Inc. | Results Trevena Announces Presentations at the American Society of Anesthesiologists 2019 Annual Meeting trevena.com ↗
Dr. Dahan presented the findings from a clinical utility function analysis of the ventilatory response to hypercapnia data from the Phase 1 proof-of-concept study comparing oliceridine to IV morphine in healthy human volunteers. |
| 2019-06-24 | Trevena Inc. | Results Trevena Announces Publication of APOLLO-2 Results in Pain Practice trevena.com ↗ |
| 2019-03-11 | Trevena Inc. | Results Trevena Announces Publication of APOLLO-1 Results in The Journal of Pain Research Highlighting Oliceridine’s Potential for Management of Moderate-to-Severe Acute Pain trevena.com ↗
“In this study, oliceridine was found to provide relief that was statistically superior to placebo in patients with moderate-to-severe acute post-surgical pain,” said Dr. Viscusi. |
| 2019-01-28 | Trevena Inc. | Regulatory Trevena Announces Receipt of Type A Meeting Minutes and Provides Regulatory Update for Oliceridine trevena.com ↗
Trevena, Inc. (NASDAQ: TRVN) today announced the receipt of the official Type A meeting minutes from the U.S. Food and Drug Administration (FDA) regarding the Complete Response Letter (CRL) received for the oliceridine New Drug Application (NDA). |
| 2018-11-02 | Trevena Inc. | Regulatory Trevena Receives Complete Response Letter for Oliceridine from FDA trevena.com ↗
Trevena, Inc. (NASDAQ: TRVN) today announced the Company has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for oliceridine. |
| 2018-10-11 | Trevena Inc. | Regulatory Trevena Announces Oliceridine FDA Advisory Committee Meeting Outcome trevena.com ↗
At the meeting, the Advisory Committee voted 8 against, and 7 in favor of, the approval of oliceridine for the management of moderate to severe acute pain in adult patients for whom an intravenous (IV) opioid is warranted. |
| 2018-05-22 | Trevena Inc. | Results Trevena announces presentations at the American Society of Colon and Rectal Surgeons 2018 Annual Scientific Meeting trevena.com ↗
Results of the trial showed that oliceridine can be successfully substituted for conventional IV opioids to manage moderate to severe acute pain. |
| 2018-01-02 | Trevena Inc. | Regulatory Trevena Announces FDA Acceptance for Review of New Drug Application for OLINVO™ (oliceridine) Injection trevena.com ↗
Trevena, Inc. (NASDAQ:TRVN) today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s New Drug Application (NDA) for OLINVO™ (oliceridine) Injection. |
| 2017-11-07 | Trevena Inc. | Results Trevena Reports Third Quarter 2017 Financial Results and Announces New Positive Clinical Trial Data trevena.com ↗
Data for all 768 patients administered OLINVO are now final, and highlight the effectiveness and utility of OLINVO in treating patients who require an IV opioid to manage pain. |
| 2017-11-02 | Trevena Inc. | Regulatory Trevena Announces Submission of New Drug Application to U.S. FDA for OLINVO™ (oliceridine injection) trevena.com ↗
Trevena, Inc. (NASDAQ:TRVN) today announced that it has recently submitted its New Drug Application (NDA) for OLINVO TM (oliceridine injection) to the U.S. Food and Drug Administration (FDA). |
| 2017-10-25 | Trevena Inc. | Results Trevena Announces Publication and Presentations of OLINVO™ (oliceridine injection) Clinical Data trevena.com ↗
The Company also announced that results of its Phase 2b trial of Breakthrough Therapy-designated OLINVO (oliceridine injection) have been published in the peer-reviewed Journal of Pain Research. |
| 2017-07-20 | Trevena Inc. | Results Trevena To Host 2017 Analyst Day and Announce Results of ATHENA Open Label Safety Study of OLINVO trevena.com ↗
Topline results from ATHENA safety study further support potential value of OLINVO in patients at risk of opioid-related adverse events |
| 2017-04-06 | Trevena Inc. | Results Trevena Announces Presentations at the 42nd Annual Regional Anesthesiology and Acute Pain Medicine Meeting trevena.com ↗
The data showed significant efficacy of OLINVO in managing moderate-to-severe acute pain, and included head-to-head comparisons to IV morphine suggesting that OLINVO could be a valuable new analgesic option for patients at risk of opioid-related adverse events. |
| 2017-02-21 | Trevena Inc. | Results Trevena Announces Positive Top-line Results from Two Phase 3 Pivotal Efficacy Studies of Intravenous Oliceridine in Moderate-to-Severe Acute Pain trevena.com ↗
Trevena, Inc. (NASDAQ:TRVN) today announced positive top-line results from its Phase 3 APOLLO-1 and APOLLO-2 pivotal efficacy studies of oliceridine in moderate-to-severe acute pain following bunionectomy and abdominoplasty, respectively. |
| 2016-10-27 | Trevena Inc. | Results Trevena Announces Highlights from Recent Presentations trevena.com ↗
Two oral podium presentations reviewed results from Phase 2 studies of oliceridine, including comparisons of oliceridine to morphine. |
| 2016-02-22 | Trevena Inc. | Regulatory Trevena, Inc. Receives FDA Breakthrough Therapy Designation for Oliceridine for the Management of Moderate-to-Severe Acute Pain trevena.com ↗
Trevena, Inc. (NASDAQ:TRVN), a clinical stage biopharmaceutical company focused on the discovery and development of biased ligands targeting G protein coupled receptors, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to the Company's lead product candidate, intravenous oliceridine (TRV130), for the management of moderate-to-severe acute pain. |
| 2015-12-03 | Trevena Inc. | Regulatory Trevena Announces FDA Grant of Fast Track Designation to Oliceridine (TRV130) for the Management of Moderate-to-Severe Acute Pain trevena.com ↗ |
| 2015-09-29 | Trevena Inc. | Results Trevena Announces Publication of TRV130 Phase 2 Bunionectomy Data in the Journal PAIN® trevena.com ↗
The results successfully demonstrated proof of concept for TRV130, and suggested potential differentiation from morphine. |
| 2015-08-31 | Trevena Inc. | Results Trevena Announces Positive Results from Phase 2b Study of TRV130 in Acute Postoperative Pain trevena.com ↗
Trevena, Inc. (NASDAQ: TRVN), a clinical stage pharmaceutical company focused on the discovery and development of biased ligands targeting G protein coupled receptors (GPCRs), today announced positive data from its randomized, double-blind, placebo- and active-controlled Phase 2b trial of TRV130 in moderate to severe acute postoperative pain after abdominoplasty surgery. |
| 2014-11-17 | Trevena Inc. | Results Trevena Announces Positive Top-Line Results from Phase 2a/b Study of TRV130 in Acute Postoperative Pain trevena.com ↗
At doses of 2 mg and 3 mg TRV130 administered every 3 hours, the study achieved its primary endpoint of statistically greater pain reduction than placebo over 48 hours, successfully demonstrating proof of concept for TRV130. |
| 2014-06-24 | Trevena Inc. | Results Results of Phase 1b Clinical Trial Comparing Trevena’s TRV130 to Morphine Published in the Journal Pain trevena.com ↗
These data suggest that TRV130 may reduce patients’ pain more effectively, act more quickly, produce less severe GI side effects and reduce the risk of respiratory depression compared to existing opioids, resulting in an improved margin of safety for dosing. |
| 2014-05-02 | Trevena Inc. | Results Trevena Presents Results from Phase 1b Trial of Injectable Analgesic TRV130 at American Society of Pain Annual Meeting trevena.com ↗
In the study, TRV130 was generally well tolerated and produced greater analgesia compared to morphine with less reduction in respiratory drive, less vomiting, and less severe nausea in healthy subjects. |
| 2013-10-15 | Trevena Inc. | Results First Clinical Experience of Trevena's lead CNS Biased Ligand, TRV130, Published in Journal of Clinical Pharmacology trevena.com ↗
At these low pharmacologically active doses, as measured by pupil constriction, study subjects experienced no nausea and vomiting. |
| 2013-03-18 | Trevena Inc. | Results Trevena to Present First-in-Man Study Results for Mu-Opioid Biased Ligand TRV130 trevena.com ↗
In this study, which was completed in 2012, TRV130 was safe and generally well-tolerated, and showed pharmacodynamic effects that were consistent with its exciting preclinical profile. |
| 2013-01-23 | Trevena Inc. | Results Trevena GPCR platform yields a novel mu-opioid biased ligand analgesic with side effect benefits trevena.com ↗
In preclinical studies, TRV130 was powerfully analgesic with an improved safety and tolerability profile when compared directly to morphine. |
| 2012-11-14 | Trevena Inc. | Results Trevena Completes First-in-Human Study of TRV130, an Injectable Mu-Opioid Biased Ligand for Acute Pain trevena.com ↗
The drug was safe and generally well-tolerated in this study, with pharmacodynamic effects recapitulating its exciting preclinical profile. |
All press releases naming this drug 84 releases
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 37 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | oliceridine | “Effect of Postoperative Analgesia of Oliceridine Fumarate for Gastrointestinal Function Recovery in Patients Undergoing Lumbar Spine Surgery” NCT07307495 ↗26“Efficacy and Safety of Oliceridine for Moderate to Severe Acute Pain After Orthopedic Surgery” NCT06320041 ↗ |
| Known as | Oliceridina | ChEMBL registry synonym — accepted as the source's own label CHEMBL2443262 ↗ |
| Known as | Oliceridine Fumarate | “Drug: Oliceridine Fumarate” NCT06454292 ↗ |
| Known as | Oliceridine fumarate injection | “Oliceridine fumarate injection” NCT06530563 ↗ |
| Known as | Olinvyk | “Drug: Oliceridine Injection [Olinvyk]” NCT06530563 ↗ |
| Known as | Olynvik | ChEMBL registry synonym — accepted as the source's own label CHEMBL2443262 ↗ |
| Known as | TRV130 | “A Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active-controlled Study of Oliceridine (TRV130) for the Treatment of Moderate to Severe Acute Pain After Bunionectomy” NCT02815709 ↗8“Investigating Oliceridine (TRV130), a G Protein-Biased Ligand at the μ-Opioid” PMID 31162798 ↗ Jun 2019 |
| Action | Activate | “Biased agonism of the μ-opioid receptor by TRV130 increases analgesia” PMID 24954166 ↗ Jun 20141“Mu opioid receptor agonist” CHEMBL2443262 ↗ |
| Modality | Other / unclassified | “Oliceridine is a G-protein biased μ-opioid receptor agonist” NCT06619145 ↗ |
| Route | Intravenous | “Thirty healthy men received single intravenous injections of the biased ligand TRV130” PMID 24954166 ↗ Jun 2014 |
| Target | OPRM1 | “Mu opioid receptor agonist” CHEMBL2443262 ↗ |